The NEOVARE™ Hereditary Cancer Test is an easy and simple blood or saliva test that assesses the risk of developing cancer due to hereditary gene mutations and could be covered by your insurance if you meet the criteria of the National Comprehensive Cancer Network (National medical society guidelines).

Top quality clinical testing is our priority and we use the latest technologies coupled with the most convenient billing method for you. We offer two tests to effectively asses your risk of developing hereditary cancer:

NEOVARE™ DIAGNOSTIC – This test is for patients who have a strong personal or family history of being a carrier of a hereditary cancer mutation. These patients meet the national medical society guidelines and in most cases are covered by their insurance provider. Since these patients are at high risk, we combine two different technologies (NGS and Microarray) for a comprehensive diagnostic panel.

NEOVARE™ SCREEN - This test is for patients who do not meet the national medical society guideline and therefore are not covered by insurance. This, however, does not mean they have zero risk of developing hereditary cancer. It only means that hey are not at a higher risk than the average population. Since the national medical society guidelines don't cover all types of hereditary cancers, we offer our patients this test using Microarray Technology at the nominal price of $150. The test is considered a screening test as it utilizes this technology to asses the 24,000 most common hereditary cancer mutations.

Hereditary Cancer Panels

  1. Pancreatic Cancer Risk Assessment Panels

    (19 Gene’s panels including Lynch Syndrome plus full genes BRCA1/BRCA2)

    APC BRCA2 MEN1 NF1 STK11
    ATM CDK4 MLH1 PALB2 TP53
    BMPR1A CDKN2A MSH2 PMS2 VHL
    BRCA1 EPCAM MSH6 SMAD4
  2. Hereditary Breast Cancer Risk Panel

    (16 Gene’s panel plus full genes BRCA1/BRCA2)

    ATM BRIP1 MUTYH PTEN STK11
    BARD1 CDH1 NBN RAD50 TP53
    BRCA1 CHEK2 NF1 RAD51C
    BRCA2 MRE11A PALB2 RAD51D
  3. Lynch Syndrome & Hereditary Colon Cancer Panel

    (19 Gene’s Panel including mutations and deletions/duplications)

    APC CHEK2 MSH3 PMS2 SMAD4
    AXIN2 EPCAM MSH6 POLD1 STK11
    BMPR1A MLH1 MUTYH POLE TP53
    CDH1 MSH2 NTHL1 PTEN
  4. BRCA1/BRCA2

    (Full Gene’s sequencing, deletions and duplications analyses)

    BRCA1 BRCA2
  5. NEOVARE PORTFOLIO:

    APC CDH1 MLH1 PALB2 RET
    ATM CDK4 MRE11A PDGFRA SDHA
    AXIN2 CDKN2A MSH2 PMS2 SDHB
    BAP1 CHEK2 MSH3 POLD1 SDHC
    BARD1 EPCAM MSH6 POLE SDHD
    BMPR1A HOXB13 MUTYH PTEN SMAD4
    BRIP1 KIT NBN RAD50 STK11
    BRCA1 MEN1 NF1 RAD51C TP53
    BRCA2 MITF NTHL1 RAD51D VHL

QUESTIONNAIR